Table S1 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma

2026 Open access

Read full text
Authors: Larissa Anastácio da Costa Carvalho, Nataliya Tovbis Shifrin, Manali S. Phadke, Michael F. Emmons, Ximo Pechuan-Jorge, Felix Mbuga, Oscar E. Ospina, Christopher Chow, Lillian Seu, Olivia L. Rose, Aparna Madhukeshwar Hegde, Nikhil I. Khushalani
+2 more Elsa Quintana, Keiran S.M. Smalley
DOI: 10.1158/2326-6066.31028303
Cited by: 0

Abstract

Supplemental Table 1: Melanoma cell lines with Q61 and G13 NRAS mutations are sensitive to RAS(ON) multi-selective inhibition in vitro. RMC-7977 potently inhibited the growth of the mouse OSUMMER 1, 2, 3, 4, 5, 9, 11, 12 and 13 cells, SW1 and IPC298 cells with a similar potency.

Fields of Study & Subjects

Melanoma and MAPK Pathways Immunotherapy and Immune Responses S100 Proteins and Annexins

Publication details

Publication date
8 January 2026